Our Products

"Valeo Pharma is focused on bringing products to Canadian physicians, providing them with more choice to meet the ever increasing needs of their patients."

- Marc Léger, Executive VP, Commercial Operations

Synacthen® Depot

Valeo Pharma currently markets PrSynacthen® Depot (1mg/mL). Synacthen is a synthetic ACTH product that is used in conditions where the production of natural cortisol and other hormones is desired. There are currently 17 indications for Synacthen approved by Health Canada. These include:

  • Acute exacerbations of Multiple Sclerosis
  • Rheumatoid arthritis
  • Lupus Erythematosus
  • Bell's Palsy
  • Ulcerative Colitis
  • Psoriatic Arthritis
  • Scleroderma
  • Nephrotic Syndrome
  • Adjuvant Treatment in cases of acute gout

For further information please consult the product monograph.

Synacthen® is a registered trademark of Novartis AG and is used under licence by Questcor Operations Ltd.


M-Eslon is a narcotic analgesic distributed by Valeo Pharma in Canada through a license from Ethypharm S.A.


Onstryv® (safinamide tablets) is a product licensed to Valeo Pharma by Zambon S.p.A and is the first new oral medication approved for Parkinson's Disease in Canada in over 10 years. Parkinson's Disease affects approximately 100,000 Canadians with approximately 6,600 new cases being diagnosed each year.

Ontryv® is indicated as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease in patients experiencing "off" episodes while on a stable dose of levodopa.

The product has been approved by Health Canada on January 10th, 2019. Commercialization of Onstryv should commence in the second quarter of fiscal year 2019.

For further information please consult the product monograph.


Utrogestan is a new vaginal capsule, containing 200mg of micronized progesterone, licensed to Valeo Pharma by Besins Healthcare in France. Utrogestan is indicated for luteal phase support during In Vitro Fertilization (IVF) cycles.

The product has already received Health Canada approval. Commercialization is expecting to start in the second quarter of fiscal year 2019.

Ethacrynate Sodium

Developed by Valeo, Ethacrynate Sodium is a loop diuretic used to treat high blood pressure and the swelling caused by diseases like congestive heart failure, liver failure, and kidney failure. Unlike other loop diuretics, Ethacrynate Sodium is not a sulfonamide and thus, its use is not contraindicated in those with sulfa allergies.

Valeo owns the worldwide rights to the product (except for Italy) . Approval to market the product in Canada has been received, and the Corporation has initiated commercialization of the product.

Valeo also intends to commercialize the product in the United States via a distribution partner, Princeton Biopharma, LLC. Princeton and Valeo have filed a dossier with the FDA in order to obtain marketing approval. Approval is pending.

For further information please consult the product monograph.

Valeo Pharma intends to pursue additional product and pipeline opportunities in the areas of Neurology, Woman's Health, and Hospital Products, and potentially in other therapeutic areas, through targeted business development efforts. Our experienced management team has a long and proven track record of successfully sourcing, developing and commercializing drugs in a variety of therapeutic areas at all stages of their life cycle in Canada.